Table 3.

Association between ABCB1 2677G>T/A genotypes and progression-free and overall survival by extent of residual disease

ABCB1 genotypeCases, n (%)Relapse, n (%)Died, n (%)Progression-free survival, HR (95% CI), P value
UnadjustedAdjusted
Optimally debulked (residual disease ≤1 cm)
    GG63 (28.6)44 (38.3)16 (35.6)1.001.00
    GA/GT110 (50.0)52 (45.2)20 (44.4)0.55 (0.37-0.82), P = 0.0040.64 (0.43-0.96), P = 0.03
    TT/TA47 (21.4)19 (16.5)9 (20.0)0.43 (0.25-0.74), P = 0.0020.51 (0.30-0.89), P = 0.02
    GA/GT + TT/TA157 (71.4)71 (61.7)29 (64.4)0.51 (0.35-0.75), P = 0.0010.60 (0.41-0.88), P = 0.01
Suboptimally debulked (residual disease >1 cm)
    GG17 (28.3)13 (26.0)16 (50.0)1.001.00
    GA/GT28 (46.7)23 (46.0)10 (31.2)1.24 (0.62-2.48), P = 0.51.23 (0.62-2.46), P = 0.5
    TT/TA15 (25.0)14 (28.0)6 (18.7)1.61 (0.75-3.45), P = 0.21.61 (0.75-3.45), P = 0.2
    GA/GT + TT/TA43 (71.7)37 (74.0)16 (50.0)1.36 (0.72-2.59), P = 0.31.35 (0.71-2.57), P = 0.3
  • * χ2 test for trend in progression-free or overall survival by increasing number of T/A alleles.

  • Adjusted for FIGO stage and residual disease.